Friday, March 28, 2008 1:40:07 PM
io, what you posted wasn't the issue.
In response to the DD post wrt 2 small p drugs that got approved with difficulty, Y3 wrote
"your comment above reads that you concede Proellex will in fact be approved."
DD had clearly not conceded the point, his post did not state he did, so he told Y3 he was wrong.
How does the fact that the other drugs got to market change DD's opinion that Proellex might not?
You can debate the underlying issue all you wish, but the DD post cleary did not "read" as Y3 posted.
I still think DD could have given a better example. Satraplatin comes quickly to mind.
In response to the DD post wrt 2 small p drugs that got approved with difficulty, Y3 wrote
"your comment above reads that you concede Proellex will in fact be approved."
DD had clearly not conceded the point, his post did not state he did, so he told Y3 he was wrong.
How does the fact that the other drugs got to market change DD's opinion that Proellex might not?
You can debate the underlying issue all you wish, but the DD post cleary did not "read" as Y3 posted.
I still think DD could have given a better example. Satraplatin comes quickly to mind.
Recent RPRX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2026 01:20:12 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/20/2026 08:23:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/15/2026 08:38:40 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/14/2026 09:22:49 PM
- Form 13F-NT - Quarterly report filed by institutional managers, Notice • Edgar (US Regulatory) • 05/14/2026 06:29:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2026 09:14:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2026 09:12:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2026 09:10:50 PM
- Royalty Pharma to present at upcoming investor conferences • GlobeNewswire Inc. • 05/07/2026 08:15:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/06/2026 01:04:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:31:54 AM
- Royalty Pharma reports first quarter 2026 results • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/30/2026 09:54:06 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/28/2026 09:00:16 PM
- Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation • GlobeNewswire Inc. • 04/21/2026 05:00:00 PM
- Royalty Pharma Declares Second Quarter 2026 Dividend • GlobeNewswire Inc. • 04/17/2026 12:30:00 PM
- Royalty Pharma to Announce First Quarter 2026 Financial Results on May 6, 2026 • GlobeNewswire Inc. • 04/15/2026 08:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/13/2026 01:53:04 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/10/2026 08:11:03 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 08:10:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 09:58:57 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/01/2026 08:55:58 PM
- Royalty Pharma signs $500M co-development agreement with J&J • IH Market News • 03/30/2026 12:28:19 PM
